Page last updated: 2024-11-07

1-hydroxymethylmidazolam

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

1-hydroxymethylmidazolam: metabolite of midazolam [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

1-hydroxymidazolam : An imidazobenzodiazepine that is midazolam in which one of the hydrogens of the methyl group is substituted by a hydroxy group. It is the major metabolite of the anesthetic, midazolam. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID107917
CHEMBL ID1188
CHEBI ID145330
SCHEMBL ID7310758
MeSH IDM0119556

Synonyms (37)

Synonym
1'-hydroxymidazolam
1-hydroxymethylmidazolam
alpha-hydroxymidazolam
59468-90-5
1-hydroxymidazolam
1-oh-mdz
bdbm50134248
[8-chloro-6-(2-fluoro-phenyl)-4h-2,5,10b-triaza-benzo[e]azulen-1-yl]-methanol
alpha-hydroxy-midazolam
CHEMBL1188 ,
8-chloro-6-(2-fluorophenyl)-1-hydroxymethyl-4h-imidazo[1,5-a][1,4]benzodiazepine
ro 21-6347
8-chloro-6-(2-fluorophenyl)-4h-imidazo[1,5-a][1,4]benzodiazepine-1-methanol
[8-chloro-6-(2-fluorophenyl)-4h-imidazo[1,5-a][1,4]benzodiazepin-1-yl]methanol
CHEBI:145330
e5142bn92z ,
4h-imidazo(1,5-a)(1,4)benzodiazepine-1-methanol, 8-chloro-6-(2-fluorophenyl)-
unii-e5142bn92z
8-chloro-6-(2-fluorophenyl)-4h-imidazo(1,5-a)(1,4)benzodiazepine-1-methanol
1'-hydroxy midazolam
SCHEMBL7310758
ro-21-6347
.alpha.-hydroxymidazolam
DTXSID50208175
8-chloro-6-(2-fluorophenyl)-4h-imidazo[1,5-a][1,4]benzodiazepine-1-methanol; 1-hydroxymidazolam; 1'-hydroxymidazolam; ro 21-6347; ?-hydroxymidazolam; alpha-hydroxymidazolam
alpha-hydroxymidazolam 0.1 mg/ml in methanol
(e)-(8-chloro-6-(2-fluorophenyl)-4h-benzo[f]imidazo[1,5-a][1,4]diazepin-1-yl)methanol
Q27276873
alpha-hydroxymidazolam 100 microg/ml in acetonitrile
F82280
MS-25227
mfcd00871458
HY-118645
CS-0067670
AKOS040755789
alpha-hydroxymidazolam, 1mg/ml in methanol
alpha-hydroxymidazolam, 0.1mg/ml in methanol

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" Consequently, its plasma elimination half-life after discontinuation was also greatly prolonged, but this shouldn't cause very prolonged sedative effects since this metabolite is much less active than the parent drug."( The effects of acute changes in renal function on the pharmacokinetics of midazolam during long-term infusion in ICU patients.
Driessen, JJ; Guelen, PJ; Vree, TB, 1991
)
0.28
"5 mg dose, the Cmax and AUC parameters of both midazolam and 1-hydroxymethylmidazolam increased proportionally after the 15 mg dose and more than proportionally after the 30 mg dose."( Dose dependent pharmacokinetics of midazolam.
Blumenthal, HP; Bornemann, LD; Colburn, WA; Crews, T; Min, BH; Patel, IH; Rees, MM, 1985
)
0.51
" A wide interpatient variability of the main pharmacokinetic parameters of midazolam was found."( Pharmacokinetics of midazolam and its main metabolite 1-hydroxymidazolam in intensive care patients.
Boulieu, R; Fisher, C; Lehmann, B; Morlet, D; Salord, F,
)
0.13
"The pharmacodynamic interaction between midazolam and its active metabolite alpha-OH-midazolam was investigated to evaluate whether estimates of relevant pharmacodynamic parameters are possible after administration of a mixture of the two."( Characterization of the pharmacodynamic interaction between parent drug and active metabolite in vivo: midazolam and alpha-OH-midazolam.
Danhof, M; Herben, VM; Mandema, JW; Tuk, B; van Oostenbruggen, MF, 1999
)
0.3
"To investigate the pharmacokinetic and pharmacodynamic profile of midazolam administered as a concentrated intranasal spray, compared with intravenous midazolam, in healthy adult subjects."( Pharmacokinetics and pharmacodynamics of midazolam administered as a concentrated intranasal spray. A study in healthy volunteers.
Brekelmans, GJ; de Haan, GJ; Edelbroek, PM; Jonker, DM; Knoester, PD; Van Der Hoeven, RT; Vermeij, TA, 2002
)
0.31
" The total plasma concentrations of midazolam and the metabolite 1-hydroxymidazolam after both intranasal and intravenous administration were described with a single pharmacokinetic model."( Pharmacokinetics and pharmacodynamics of midazolam administered as a concentrated intranasal spray. A study in healthy volunteers.
Brekelmans, GJ; de Haan, GJ; Edelbroek, PM; Jonker, DM; Knoester, PD; Van Der Hoeven, RT; Vermeij, TA, 2002
)
0.31
"5 mg/kg) administration of MDZ, and pharmacokinetic parameters were estimated by fitting to a noncompartmental model."( Expression of the human CYP3A4 gene in the small intestine of transgenic mice: in vitro metabolism and pharmacokinetics of midazolam.
Akiyama, TE; Cheung, C; Elizondo, G; Feigenbaum, L; Gonzalez, FJ; Granvil, CP; Krausz, KW; Yu, AM, 2003
)
0.32
"Prospective population pharmacokinetic study."( Population pharmacokinetics and metabolism of midazolam in pediatric intensive care patients.
de Hoog, M; de Wildt, SN; van den Anker, JN; van der Giesen, E; Vinks, AA, 2003
)
0.32
" A population analysis was conducted via a two-compartment pharmacokinetic model by the NPEM program."( Population pharmacokinetics and metabolism of midazolam in pediatric intensive care patients.
de Hoog, M; de Wildt, SN; van den Anker, JN; van der Giesen, E; Vinks, AA, 2003
)
0.32
"We describe population and individual midazolam pharmacokinetic parameter estimates in pediatric intensive care patients by using a population modeling approach."( Population pharmacokinetics and metabolism of midazolam in pediatric intensive care patients.
de Hoog, M; de Wildt, SN; van den Anker, JN; van der Giesen, E; Vinks, AA, 2003
)
0.32
"The objective of the present investigation was to develop a population pharmacodynamic model for midazolam- and lorazepam-induced sedation upon long-term continuous infusion in critically ill patients."( Population pharmacodynamic modelling of lorazepam- and midazolam-induced sedation upon long-term continuous infusion in critically ill patients.
Danhof, M; de Jongh, J; Strack van Schijndel, RM; Swart, EL; Thijs, LG; Zuideveld, KP, 2006
)
0.33
"The pharmacokinetics of lorazepam and midazolam was described with previously proposed pharmacokinetic models."( Population pharmacodynamic modelling of lorazepam- and midazolam-induced sedation upon long-term continuous infusion in critically ill patients.
Danhof, M; de Jongh, J; Strack van Schijndel, RM; Swart, EL; Thijs, LG; Zuideveld, KP, 2006
)
0.33
"The population pharmacodynamic model shows a similarly wide intra- and inter-individual variability in the pharmacodynamics of both lorazepam and midazolam."( Population pharmacodynamic modelling of lorazepam- and midazolam-induced sedation upon long-term continuous infusion in critically ill patients.
Danhof, M; de Jongh, J; Strack van Schijndel, RM; Swart, EL; Thijs, LG; Zuideveld, KP, 2006
)
0.33
" Serial blood samples were collected predose and up to 24 hours after each MDZ dose for pharmacokinetic (PK) evaluation."( Effect of R667, a novel emphysema agent, on the pharmacokinetics of midazolam in healthy men.
Brennan, BJ; Brown, AB; Davies, BE; Gooden, C; Kolis, SJ; Rutman, O, 2006
)
0.33
" This method was sensitive and reliable enough for pharmacokinetic studies on healthy volunteers, and was applied for the measurement of CYP3A activity in humans after an intravenous (1mg) and a single-oral administration (2mg) of subtherapeutic MDZ dose."( A developed determination of midazolam and 1'-hydroxymidazolam in plasma by liquid chromatography-mass spectrometry: application of human pharmacokinetic study for measurement of CYP3A activity.
Kanazawa, H; Murakami, I; Shimizu, M; Sugawara, K; Tamura, HO; Tateishi, T; Uno, T, 2007
)
0.34
" This study was undertaken to estimate whether the CYP3A5 genotype can explain a relevant portion of pharmacokinetic interindividual variability."( Impact of the CYP3A5 genotype on midazolam pharmacokinetics and pharmacodynamics during intensive care sedation.
Bachmakov, I; Bremer, F; Fromm, MF; König, J; Schüttler, J; Schwilden, H, 2007
)
0.34
" Serial plasma samples were collected for pharmacokinetic analyses."( The effect of multiple-dose, oral rifaximin on the pharmacokinetics of intravenous and oral midazolam in healthy volunteers.
Bettenhausen, DK; Connolly, M; Forbes, WP; Pentikis, HS; Trapnell, CB, 2007
)
0.34
"The pharmacokinetic parameters of single-dose intravenous or oral midazolam were determined alone and after coadministration of rifaximin for 3 and 7 days."( The effect of multiple-dose, oral rifaximin on the pharmacokinetics of intravenous and oral midazolam in healthy volunteers.
Bettenhausen, DK; Connolly, M; Forbes, WP; Pentikis, HS; Trapnell, CB, 2007
)
0.34
"ESRD can affect the pharmacokinetic disposition of drugs subject to nonrenal clearance."( ESRD impairs nonrenal clearance of fexofenadine but not midazolam.
Frye, RF; Himmelfarb, J; Le, P; Leblond, FA; Naud, J; Nolin, TD; Pichette, V; Sadr, H, 2009
)
0.35
" Population pharmacokinetic modeling identified a significant relationship between temperature and clearance and intercompartmental clearance for midazolam."( Mild hypothermia alters midazolam pharmacokinetics in normal healthy volunteers.
Bies, RR; Callaway, CW; Empey, PE; Hostler, D; Kochanek, PM; Poloyac, SM; Rittenberger, JC; Tortorici, MA; Zhou, J, 2010
)
0.36
" Pharmacokinetic changes are expected because of extracorporeal circulation and maturation."( Population pharmacokinetics of midazolam and its metabolites during venoarterial extracorporeal membrane oxygenation in neonates.
Ahsman, MJ; Hanekamp, M; Mathot, RA; Tibboel, D; Wildschut, ED, 2010
)
0.36
" Midazolam, 1'-hydroxymidazolam, digoxin, and telaprevir concentrations in plasma and digoxin concentrations in urine were measured and pharmacokinetic parameters calculated."( Effect of telaprevir on the pharmacokinetics of midazolam and digoxin.
Alves, K; Chandorkar, G; Farmer, HF; Garg, V; Smith, F; van Heeswijk, RP, 2012
)
0.38
" Pharmacokinetic analysis, on whole blood, revealed rapid absorption of the administered midazolam with a higher C(max) in PXB compared to SCID."( Pharmacokinetics and metabolism of midazolam in chimeric mice with humanised livers.
Hutchison, M; Morikawa, Y; Pickup, K; Samuelsson, K; Sarda, S; Schulz-Utermoehl, T; Swales, JG; Wilson, ID, 2012
)
0.38
"We aim to evaluate the influence of covariates, including cytochrome P450 3A (CYP3A) genetic polymorphisms, on the pharmacokinetics of midazolam (MDZ) in Asian cancer patients, using a population pharmacokinetic approach."( CYP3A5*3 and bilirubin predict midazolam population pharmacokinetics in Asian cancer patients.
Goh, BC; Hee, KH; Lee, LS; Sapari, NS; Seng, KY; Soon, GH; Soong, R, 2014
)
0.4
"9% reduction in Cmax (120 and 180 mg kg(-1), respectively) compared with the control."( Effect of triacontanol on the pharmacokinetics of docetaxel in rats associated with induction of cytochrome P450 3A1/2.
Chen, X; Deng, S; Fan, A; Gao, W; Li, C; Li, N; Liu, Q; Wang, C; Wen, X; Zhang, Q; Zhang, W; Zhang, Y; Zhao, D; Zhao, J, 2014
)
0.4
" Population pharmacokinetic analysis was performed using nonlinear mixed effects modeling."( Population pharmacokinetic analysis of circadian rhythms in hepatic CYP3A activity using midazolam.
Di Gion, P; Frechen, S; Fuhr, U; Kerkweg, U; Kraus, D; Queckenberg, C; Rokitta, D; Suleiman, AA; Tomalik-Scharte, D, 2014
)
0.4
" To find clinically relevant parameters for dose individualization, we performed a pharmacokinetic study on midazolam, 1OH-midazolam (1-OH-M) and 1OH-midazolam-glucuronide (1-OH-MG) in terminally ill patients."( Hypoalbuminaemia and decreased midazolam clearance in terminally ill adult patients, an inflammatory effect?
Baar, FPM; de Winter, BCM; Franken, LG; Koch, BCP; Masman, AD; Mathot, RAA; Tibboel, D; van Gelder, T, 2017
)
0.46
"2), a population pharmacokinetic analysis was conducted with 192 samples from 45 terminally ill patients who received midazolam either orally or subcutaneously."( Hypoalbuminaemia and decreased midazolam clearance in terminally ill adult patients, an inflammatory effect?
Baar, FPM; de Winter, BCM; Franken, LG; Koch, BCP; Masman, AD; Mathot, RAA; Tibboel, D; van Gelder, T, 2017
)
0.46
" Non-compartmental pharmacokinetic methods were used to calculate main pharmacokinetic parameters and absolute bioavailability."( A Two-way Randomized Cross-over Pharmacokinetic and Pharmacodynamic Study of an Innovative Oral Solution of Midazolam (ADV6209).
Burton, I; Granier, LA; Guittet, C; Manso, M; Marçon, F, 2017
)
0.46
" Pharmacokinetic samples were collected over 24 hours on days 1 and 8, then analyzed using liquid chromatography-tandem mass spectrometry."( The Effect of GS-548351 on the Pharmacokinetics of Midazolam Following Multiple Doses of ANS-6637 in Healthy Adults.
Aepfelbacher, J; Bunn, HT; George, JM; Kattakuzhy, S; Kottilil, S; Masur, H; Mathur, P; McLaughlin, M; Proschan, M; Rosenthal, E; Vijan, A, 2020
)
0.56
" Multiple models have been developed for midazolam, the typical probe substrate for CYP3A activity, but no population pharmacokinetic models have been developed for use with inhibition or induction."( Composite midazolam and 1'-OH midazolam population pharmacokinetic model for constitutive, inhibited and induced CYP3A activity.
Meid, AD; Mikus, G; Wiebe, ST, 2020
)
0.56
" Full pharmacokinetic profiles of midazolam and 1-hydroxymidazolam on days 0 and 14 and safety data were obtained."( Effects of Repeated Oral Administration of Esaxerenone on the Pharmacokinetics of Midazolam in Healthy Japanese Males.
Furuie, H; Igawa, Y; Ishizuka, H; Ishizuka, T; Kato, M; Kuroda, K; Nishikawa, Y; Okuda, Y; Shimizu, T; Toyama, K, 2021
)
0.62

Bioavailability

ExcerptReferenceRelevance
" Significant changes in the Cmax, tmax, and AUC parameters for both midazolam and its metabolite were seen when midazolam was ingested one hour after a meal: There was a delayed and reduced rate of absorption as well as a small reduction in the extent of absorption."( Influence of food on midazolam absorption.
Bornemann, LD; Chen, SS; Crews, T; Patel, IH; Twardak, S, 1986
)
0.27
" The rectal bioavailability was 40-65% (mean 52%) and the terminal half-life was 114-305 min (mean 161 min)."( Pharmacokinetics of midazolam and alpha-hydroxy-midazolam following rectal and intravenous administration.
Clausen, TG; Crevoisier, C; Dixon, JS; Hansen, PB; Larsen, F; Rasmussen, SN; Wolff, J, 1988
)
0.27
"Studies in humans in vivo have demonstrated that substances found in grapefruit juice may increase the bioavailability of dihydropyridine derivatives as a result of the inhibition of liver enzyme activities by flavonoids found in grapefruit."( In vitro inhibition of midazolam and quinidine metabolism by flavonoids.
Chen, J; Follath, F; Freiburghaus, AU; Ha, HR; Leuenberger, PM, 1995
)
0.29
" Despite complete oral absorption, measured oral bioavailability was on average about 50% less than that predicted on the assumption that only the liver contributed to first-pass metabolism."( Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism.
Kunze, KL; O'Shea, D; Paine, MF; Perkins, JD; Shen, DD; Thummel, KE; Wilkinson, GR, 1996
)
0.29
"The aim of this study was to determine the bioavailability and absorption kinetics of midazolam given as an intranasal (i."( Pharmacokinetics of midazolam given as an intranasal spray to adult surgical patients.
Björkman, S; Idvall, J; Rigemar, G, 1997
)
0.3
" Rapid uptake and high bioavailability were demonstrated."( Pharmacokinetics and pharmacodynamics of midazolam administered as a concentrated intranasal spray. A study in healthy volunteers.
Brekelmans, GJ; de Haan, GJ; Edelbroek, PM; Jonker, DM; Knoester, PD; Van Der Hoeven, RT; Vermeij, TA, 2002
)
0.31
"Grapefruit juice inhibits CYP3A4 in the intestinal wall leading to a reduced intestinal first pass metabolism and thereby an increased oral bioavailability of certain drugs."( Intestinal first pass metabolism of midazolam in liver cirrhosis --effect of grapefruit juice.
Andersen, V; Larsen, NE; Larsen, S; Pedersen, N; Sonne, J, 2002
)
0.31
" Therefore, RH40 might be used to prepare drug formulations in pharmaceutical industry and would increase the bioavailability of some drugs transformed by CYP3As and further lead to significant clinical pharmacologic effects."( [Effect of polyoxyl ether analogous surfactants on the activity of cytochromes P450 3A in rats in vivo].
Cao, L; Li, G; Qiu, J; Ren, XH; Si, LQ; Yao, J, 2008
)
0.35
" The following pharmacokinetic parameters were included for the analysis: MDZ oral and systemic clearance, area under the concentration-time curve (AUC) of oral and intravenous MDZ, MDZ oral bioavailability (F), and MDZ gastrointestinal extraction (E(G))."( Sex-dependent differences in cytochrome P450 3A activity as assessed by midazolam disposition in humans: a meta-analysis.
Hu, ZY; Zhao, YS, 2010
)
0.36
" The time-course of drug-drug interactions due to clarithromycin will vary with the relative contribution of intestinal and hepatic CYP3A to the clearance and bioavailability of a victim substrate."( Rate of onset of inhibition of gut-wall and hepatic CYP3A by clarithromycin.
Chalasani, N; Gorski, JC; Hall, SD; Hamman, MA; Malireddy, SR; Quinney, SK; Vuppalanchi, R, 2013
)
0.39
"The objective of this study was to assess the bioavailability and the sedative effect of a single-dose administration of an innovative oral solution of midazolam containing γ-cyclodextrins (ADV6209)."( A Two-way Randomized Cross-over Pharmacokinetic and Pharmacodynamic Study of an Innovative Oral Solution of Midazolam (ADV6209).
Burton, I; Granier, LA; Guittet, C; Manso, M; Marçon, F, 2017
)
0.46
"A bioavailability study with a standard two-sequences, two-periods, and crossover design was conducted."( A Two-way Randomized Cross-over Pharmacokinetic and Pharmacodynamic Study of an Innovative Oral Solution of Midazolam (ADV6209).
Burton, I; Granier, LA; Guittet, C; Manso, M; Marçon, F, 2017
)
0.46
" ADV6209 had a bioavailability of 39."( A Two-way Randomized Cross-over Pharmacokinetic and Pharmacodynamic Study of an Innovative Oral Solution of Midazolam (ADV6209).
Burton, I; Granier, LA; Guittet, C; Manso, M; Marçon, F, 2017
)
0.46
"Cyclodextrins have little impact on midazolam oral bioavailability and the pharmacokinetics parameters of midazolam formulation ADV6209 are close to those reported previously."( A Two-way Randomized Cross-over Pharmacokinetic and Pharmacodynamic Study of an Innovative Oral Solution of Midazolam (ADV6209).
Burton, I; Granier, LA; Guittet, C; Manso, M; Marçon, F, 2017
)
0.46

Dosage Studied

ExcerptRelevanceReference
" Under basolateral sink conditions and low apical MDZ dosing concentration (1-8 microM), the first-pass extraction ratio was found to be approximately 15%."( First-pass midazolam metabolism catalyzed by 1alpha,25-dihydroxy vitamin D3-modified Caco-2 cell monolayers.
Calamia, JC; Fisher, JM; Kunze, KL; Schmiedlin-Ren, P; Shen, DD; Thummel, KE; Watkins, PB; Wrighton, SA, 1999
)
0.3
"Midazolam and metabolites were dosed in plasma and ultratiltration liquid by chromatography."( [Use of midazolam in postoperative sedation of patients with multiple organ failure treated with hemodiafiltration. Clinical study and pharmacokinetics].
Bastien, O; Bolon, M; Boulieu, R; Flamens, C; Lehot, JJ, 2002
)
0.31
" After repeated NN703 dosing (day 9), NN703 levels reached steady state, and midazolam AUC further increased to 93% relative to baseline (P=0."( A clinical study investigating the pharmacokinetic interaction between NN703 (tabimorelin), a potential inhibitor of CYP3A4 activity, and midazolam, a CYP3A4 substrate.
Christiansen, T; Ilondo, MM; Olsen, AK; Rasmussen, MH; Schulz, R; Taub, ME; Thomsen, MS; Zdravkovic, M, 2003
)
0.32
" No significant difference in the AUC after oral dosing of MDZ was noted between sexes."( Sex-dependent differences in cytochrome P450 3A activity as assessed by midazolam disposition in humans: a meta-analysis.
Hu, ZY; Zhao, YS, 2010
)
0.36
" Pharmacokinetics (PK) and biotransformation of MDZ were investigated following dosing to Cyp2c KO and wild type mice before and after TAO treatment."( Drug-drug interactions and metabolism in cytochrome P450 2C knockout mice: application to troleandomycin and midazolam.
Gallagher, R; Grimsley, A; Hutchison, M; Pickup, K; Samuelsson, K; Wilson, ID, 2013
)
0.39
" Hepatic clearance of docetaxel was enhanced in vitro and in vivo at dosage of 120 and 180 mg kg(-1), and CYP3A activity was up-regulated by measuring the formation rate of 1-hydroxymidazolam."( Effect of triacontanol on the pharmacokinetics of docetaxel in rats associated with induction of cytochrome P450 3A1/2.
Chen, X; Deng, S; Fan, A; Gao, W; Li, C; Li, N; Liu, Q; Wang, C; Wen, X; Zhang, Q; Zhang, W; Zhang, Y; Zhao, D; Zhao, J, 2014
)
0.4
"Our study indicates albumin levels and eGFR as relevant clinical parameters to optimize midazolam dosing in terminally ill patients."( Hypoalbuminaemia and decreased midazolam clearance in terminally ill adult patients, an inflammatory effect?
Baar, FPM; de Winter, BCM; Franken, LG; Koch, BCP; Masman, AD; Mathot, RAA; Tibboel, D; van Gelder, T, 2017
)
0.46
" Its use increases in the last days of hospice patients' lives while safe dosage can be challenging."( Midazolam and hydroxymidazolam plasma concentrations can be monitored with selected biochemical and physiological parameters of palliative care patients.
Gościniak, K; Grabowski, T; Sopata, M; Stachowiak-Szymczak, K; Teżyk, A; Zaporowska-Stachowiak, I, 2021
)
0.62
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
drug metabolitenull
human blood serum metaboliteAny metabolite (endogenous or exogenous) found in human blood serum samples.
human urinary metaboliteAny metabolite (endogenous or exogenous) found in human urine samples.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (4)

ClassDescription
imidazobenzodiazepineAny organic heterotricyclic compound that is any benzodiazepine which is ortho-fused with a imidazole.
organochlorine compoundAn organochlorine compound is a compound containing at least one carbon-chlorine bond.
monofluorobenzenesAny member of the class of fluorobenzenes containing a mono- or poly-substituted benzene ring carrying a single fluorine substitutent.
aromatic primary alcoholAny primary alcohol in which the alcoholic hydroxy group is attached to a carbon which is itself bonded to an aromatic ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Cytochrome P450 3A4Homo sapiens (human)IC50 (µMol)10.00000.00011.753610.0000AID54753
5-hydroxytryptamine receptor 2ARattus norvegicus (Norway rat)IC50 (µMol)10.00000.00040.908610.0000AID54753
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (19)

Processvia Protein(s)Taxonomy
lipid hydroxylationCytochrome P450 3A4Homo sapiens (human)
lipid metabolic processCytochrome P450 3A4Homo sapiens (human)
steroid catabolic processCytochrome P450 3A4Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 3A4Homo sapiens (human)
steroid metabolic processCytochrome P450 3A4Homo sapiens (human)
cholesterol metabolic processCytochrome P450 3A4Homo sapiens (human)
androgen metabolic processCytochrome P450 3A4Homo sapiens (human)
estrogen metabolic processCytochrome P450 3A4Homo sapiens (human)
alkaloid catabolic processCytochrome P450 3A4Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 3A4Homo sapiens (human)
calcitriol biosynthetic process from calciolCytochrome P450 3A4Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 3A4Homo sapiens (human)
vitamin D metabolic processCytochrome P450 3A4Homo sapiens (human)
vitamin D catabolic processCytochrome P450 3A4Homo sapiens (human)
retinol metabolic processCytochrome P450 3A4Homo sapiens (human)
retinoic acid metabolic processCytochrome P450 3A4Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 3A4Homo sapiens (human)
aflatoxin metabolic processCytochrome P450 3A4Homo sapiens (human)
oxidative demethylationCytochrome P450 3A4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (23)

Processvia Protein(s)Taxonomy
monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
steroid bindingCytochrome P450 3A4Homo sapiens (human)
iron ion bindingCytochrome P450 3A4Homo sapiens (human)
protein bindingCytochrome P450 3A4Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
retinoic acid 4-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
oxidoreductase activityCytochrome P450 3A4Homo sapiens (human)
oxygen bindingCytochrome P450 3A4Homo sapiens (human)
enzyme bindingCytochrome P450 3A4Homo sapiens (human)
heme bindingCytochrome P450 3A4Homo sapiens (human)
vitamin D3 25-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
caffeine oxidase activityCytochrome P450 3A4Homo sapiens (human)
quinine 3-monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
testosterone 6-beta-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
1-alpha,25-dihydroxyvitamin D3 23-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 8,9 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 11,12 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 14,15 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
aromatase activityCytochrome P450 3A4Homo sapiens (human)
vitamin D 24-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
estrogen 2-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
1,8-cineole 2-exo-monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (3)

Processvia Protein(s)Taxonomy
cytoplasmCytochrome P450 3A4Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 3A4Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 3A4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (4)

Assay IDTitleYearJournalArticle
AID679579TP_TRANSPORTER: inhibition of Digoxin transepithelial transport (basal to apical)(Digoxin: 5 uM, 1-hydroxymidazolam: 100 uM) in Caco-2 cells1999Pharmaceutical research, Mar, Volume: 16, Issue:3
Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein.
AID679598TP_TRANSPORTER: inhibition of Digoxin transepithelial transport (basal to apical)(Digoxin: 0.025 uM, 1'-hydroxymidazolam: 50 uM) in MDR1-expressing LLC-PK1 cells2001European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, Feb, Volume: 12, Issue:4
Inhibitory effects of CYP3A4 substrates and their metabolites on P-glycoprotein-mediated transport.
AID54753Binding affinity for Cytochrome P450 3A4; Range = 1-10 uM2003Bioorganic & medicinal chemistry letters, Nov-03, Volume: 13, Issue:21
Design and synthesis of a new fluorescent probe for cytochrome P450 3A4 (CYP 3A4).
AID680048TP_TRANSPORTER: inhibition of Daunorubicin transepithelial transport (basal to apical)(Daunorubicin: 0.035 uM, 1'-hydroxymidazolam: 50 uM) in MDR1-expressing LLC-PK1 cells2001European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, Feb, Volume: 12, Issue:4
Inhibitory effects of CYP3A4 substrates and their metabolites on P-glycoprotein-mediated transport.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (160)

TimeframeStudies, This Drug (%)All Drugs %
pre-199015 (9.38)18.7374
1990's32 (20.00)18.2507
2000's54 (33.75)29.6817
2010's49 (30.63)24.3611
2020's10 (6.25)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 9.44

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index9.44 (24.57)
Research Supply Index5.35 (2.92)
Research Growth Index4.78 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (9.44)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials46 (28.22%)5.53%
Reviews1 (0.61%)6.00%
Case Studies2 (1.23%)4.05%
Observational1 (0.61%)0.25%
Other113 (69.33%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]